GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

After a year of controversy and complaints, Sen. Elizabeth Warren is asking a federal watchdog to investigate GSK over its ...

Discover GSK's impressive stock surge, boosted by strong earnings, a share buyback program, and a focus on specialty medicines.

The stock of GlaxoSmithKline Pharmaceuticals (GSK Pharma) hit a three-month high of ₹2,640 a share as it surged 5 per cent on Monday before closing at ₹2,638. During the past seven trading days, the ...

(Continued from "Pharma news highlights: court cases, controversy and increased transparency efforts") Unarguably, the most sensational item over the past few weeks has been the GlaxoSmithKline ...

London: GSK plc has announced that Dr Gavin Screaton will join the Board of the Company as a Non-Executive Director from 1 May 2025. Dr Screaton's appointment follows a search to replace the skills ...

GSK plc has completed its previously announced acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of ...

GSK plc (NYSE:GSK) Price Target Upside: 29.94% GSK plc (NYSE:GSK), formerly known as GlaxoSmithKline, is a global pharmaceutical and healthcare corporation based in the United Kingdom that creates ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other ...